
    
      The Synovate Study is a global, randomized, double-blind, placebo-controlled, phase 3 study
      in patients with unresectable, locally-advanced or metastatic New York esophageal squamous
      cell carcinoma 1 (NY-ESO-1) positive synovial sarcoma following first-line systemic
      anti-cancer therapy.
    
  